

- hyperkalemia, 310  
hypertension, 6e-4  
lipoprotein disorders, 2443–2444  
oral pigmentation, 240t  
venous thrombosis, 744  
for amenorrhea, 337  
breast cancer risk and, 524  
contraindications to, 334, 2391, 2391t  
drug interactions of, 42t, 44, 2559  
for dysmenorrhea, 339  
formulations of, 2390–2391  
for hirsutism, 334  
HIV infection risk and, 1221  
in perimenopause, 2382  
for polycystic ovarian syndrome, 337
- Oral-facial-digital syndrome type I, 1850t
- Oral glucose tolerance test, 2401, 2401t
- Oral hairy leukoplakia, 1188, 1188f, 1190, 1255, 1256f
- Oral mucosa  
age-related changes in, 242  
diseases of  
pigmented lesions, 240t  
ulcers, 237  
vesicular, bullous, or ulcerative lesions, 238–239t  
white lesions, 240t
- Oral pain, nondental, 237, 239
- Oral rehydration solution (ORS)  
for cholera, 1063–1064, 1064t  
composition of, 856, 1058, 1063, 1064t  
for infectious diarrhea, 267, 856, 857t  
for *Shigella* infections, 1058
- Oral sex, HIV transmission and, 1220f, 1221, 1285
- Oral ulcers, 46e-4f, 237, 239t, 2129t
- Orán virus, 1308t
- Orbit, disorders of, 207
- Orbital pseudotumor, 207, 391e-1t
- Orbitofrontal cortex, 211
- Orbiviruses, 1305, 1308t, 1319
- Orchiectomy  
for prostate cancer, 103e-3, 103e-15, 585, 586  
for testicular cancer, 590
- Orchiopexy, 588
- Orchitis  
in lepromatous leprosy, 1126  
in mumps infection, 231e-2, 231e-3  
viral, 2365
- Orexin (hypocretin), 185, 186f, 189, 215
- Orf, 220e-1t, 829
- Organic acid(s), renal transport of, 332e-8
- Organic anion transporters (OATs), 431e-1, 431e-2f
- Organic anion transport protein 1B1 (OATP1B1), 38, 2000
- Organic dusts, 1688t, 1691
- Organ of Corti, 217, 218f
- Organophosphates, 267, 473e-10t, 2688t
- Organ transplantation. *See* Solid organ transplantation
- Oriboca virus, 1309t
- Orientia tsutsugamushi*, 782, 1159. *See also* Scrub typhus
- Oritavancin  
action of, 930, 931t  
adverse effects of, 938t, 942  
drug interactions of, 939t  
indications for, 940t, 942, 976  
in pregnancy and lactation, 937t  
resistance to, 931t, 933–934
- Orlistat, 96e-8, 2397, 2453
- Ornithine decarboxylase, 246e-8
- Ornithine metabolism disorders, 434e-3t
- Ornithine transcarbamylase deficiency, 434e-3t
- Ornithodoros* spp. tick, 1146, 1147f
- Oromandibular dystonia, 2620
- Oropharyngeal disease  
cancer, 477, 502, 503, 505, 1198. *See also* Head and neck cancer  
dysphagia in, 256  
in tularemia, 1068
- Oropouche virus, 1309t, 1318
- Orotic aciduria  
hepatocellular carcinoma and, 545  
megaloblastic anemia and, 649  
in pyrimidine metabolism disorders, 431e-5t, 431e-6, 431e-6f
- Oroya fever, 1081t, 1083
- Orphenadrine, 473e-10t, 473e-13t
- ORS. *See* Oral rehydration solution (ORS)
- Orthobunyaviruses, 1305, 1308–1309t
- Orthobunyavirus infections, 1308–1309t, 1318
- Orthodoxia, 1992
- Orthodromic AV reentry, 1481, 1482f
- Orthomyxoviruses, 214e-2t, 214e-3f, 214e-4, 1305. *See also* Influenza virus
- Orthomyxovirus infections, 1311–1312t
- Orthopnea, 47e-3, 1503
- Orthopoxvirus, 220e-1t
- Orthostatic hypotension  
approach to the patient, 2639–2640  
clinical features of, 145–146, 2639, 2639t  
definition of, 1445  
diagnosis of, 2639–2640  
dizziness in, 148  
drug-related, 2640t, 2644  
etiology of, 145t, 2639t  
falls and, 165  
in hypovolemia, 298  
neurogenic, 146  
in opioid use disorders, 468e-2  
pathophysiology of, 142, 145, 146f, 1445  
in PD, 2617  
in pheochromocytoma, 1613  
prevalence of, 2639t  
treatment of, 146, 2644, 2644t
- Orthostatic proteinuria, 1834
- Orthostatic tachycardia, 298
- Orungo virus, 1308t
- OSAHS. *See* Obstructive sleep apnea/hypopnea syndrome (OSAHS)
- Osborn wave, 1457
- Oscillopsia, 148, 149
- Oseltamivir  
action of, 214e-5, 214e-9, 215e-1  
adverse effects of, 215e-1, 1213  
for influenza prophylaxis, 215e-2t, 1213t, 1214, 1252t  
for influenza treatment, 215e-2t, 215e-5, 233, 1213, 1213t  
pharmacology of, 215e-1, 215e-2t  
resistance to, 215e-1, 215e-2t
- Osler maneuver, 1626
- Osler's nodes, 1443
- Osler-Weber-Rendu syndrome (hereditary hemorrhagic telangiectasia)  
bleeding in, 403  
clinical features of, 357  
gastrointestinal bleeding in, 277  
skin manifestations of, 356t, 357, 1442  
small intestine angioma in, 536  
vascular malformations in, 732, 2585
- Oslo Study, 1134
- OSM (ocostatin M), 372e-11t
- Osmolality, 295
- Osmolar gap, 319
- Osmolytes, 301
- Osmoreceptors, 295, 332e-9–10, 332e-10f, 2274–2275
- Osmoregulation, 332e-9–10, 332e-10f, 2279f
- Osmotic demyelination syndrome, 64e-5, 301, 302
- Osmotic diarrhea, 269, 303, 1933. *See also* Diarrhea
- Osmotic diuresis, 297
- Osmotic equilibrium, 296
- Osmotic fragility, 651
- Osmotic laxatives. *See* Laxatives
- OspA, 1150
- OspC, 1150
- Ospemifene, 2383
- Ossa virus, 1309t
- Ossification, extraskelatal, 426e-7–8, 426e-7t
- Osteitis fibrosa cystica, 1815, 2472, 2487
- Osteoarthritis (OA), 2226  
in acromegaly, 2240–2241  
back pain in, 117  
clinical features of, 2230  
definition of, 2226  
diagnosis of, 2226, 2230, 2230f  
global considerations in, 2228  
joints affected by, 2226, 2226f  
hand, 2226, 2226f  
hip, 2228, 2230  
knee, 2226, 2228–2229, 2228f, 2230, 2230f  
toe, 2229f  
neck pain in, 122  
oral pain in, 237  
pain sources in, 2230  
pathogenesis of, 2226–2227, 2227f  
pathology of, 2229–2230, 2229f  
prevalence of, 2226  
risk factors for, 2227–2229, 2228f  
treatment of, 2230, 2232t  
acetaminophen, 2231  
cartilage regeneration, 2233  
COX-2 inhibitors, 2232  
exercise, 2231  
intraarticular injections, 2232  
malalignment correction, 2231  
nonpharmacotherapy, 2230–2231  
NSAIDs, 2231–2232  
opioid analgesics, 2232  
surgical, 2233
- Osteoarthropathy, hypertrophic. *See* Hypertrophic osteoarthropathy
- Osteoblast(s), 426e-1f, 2455f, 2456f, 2467
- Osteoblastic lesion, 119e-4
- Osteoblastoma, 609t
- Osteocarcinoma, 101e-2t
- Osteochondrodysplasias, 426e-7
- Osteochondroma, 119e-3
- Osteochondromatosis (multiple exostoses), 426e-7
- Osteoclast(s), 426e-1f, 2455–2456, 2455f, 2456f, 2467
- Osteoclast activating factor, 713
- Osteocyte(s), 2455
- Osteodystrophy, renal, 291, 2478
- Osteogenesis, 119e-4
- Osteogenesis imperfecta, 2507  
classification of, 2507–2508, 2508t  
clinical features of, 219, 1443, 2508–2509  
diagnosis of, 2509  
genetic considerations in, 435, 2509  
incidence of, 2508  
treatment of, 96e-5, 2509–2510
- Osteolytic lesion, 119e-4
- Osteoma cutis, 363–364
- Osteomalacia  
axial, 426e-6  
diagnosis of, 2465–2466  
in hypophosphatemia, 426e-5–6  
hypophosphatemia and, 2465  
oncogenic (tumor-induced), 609t, 612  
pathogenesis of, 462e-19, 2465  
postgastrectomy, 1927  
secondary hyperparathyroidism and, 2478  
tumor-induced, 2459, 2460
- Osteomyelitis, 838  
actinomycotic, 1088, 1089f  
anaerobic bacterial, 1099–1100, 1102  
*B. dermatitidis*, 1338  
from bite-wound infections, 167e-1  
classification of, 838–839  
clinical features of, 152e-6t  
*E. coli*, 1028  
enterococcal, 974  
foot, 845, 845f, 1046  
in long bones  
clinical features of, 842, 842f  
complications of, 843  
diagnosis of, 842  
epidemiology of, 842  
pathogenesis of, 841–842  
treatment of, 840t, 841t, 842–843  
*Nocardia*, 1087t  
nontyphoidal *Salmonella*, 1054